Last viewed: MYL


Prices are updated after-hours



nasdaq:MYL Mylan N.V.

MYL | $15.86 | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
http://mylan.co.uk
Sec Filling | Patents | 35000 employees

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

add to today's watch list email alert is off




china   brands  

Press-releases


Global Professional Acne Medication Market (2022 to 2030) - Opportunity Analysis and Industry Forecast
Published: 2022-01-19 (Crawled : 19:00) - prnewswire.com
JNJ | News | $165.98 | twitter stocktwits trandingview |
Health Technology
| | O: 0.06% H: 0.0% C: 0.0%
GSK | News | $45.1 | twitter stocktwits trandingview |
Health Technology
| | O: -1.78% H: 0.0% C: 0.0%
VTRS | $14.53 | twitter stocktwits trandingview |
Health Technology
| | O: -0.51% H: 1.6% C: -0.03%
BHC | News | $24.8 | twitter stocktwits trandingview |
Health Technology
| | O: -4.51% H: 0.0% C: 0.0%
GLAXF | News | $21.82 | twitter stocktwits trandingview |
Health Technology
| | O: 0.95% H: 0.0% C: 0.0%

acne
Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
RVNC | $13.43 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: 0.0%

fda xin injection submission
Human Growth Hormone (hGH) Market to Reach $9.21 Billion, By 2030 at 9.0% CAGR: AMR
Published: 2022-01-14 (Crawled : 01:00) - prnewswire.com
VTRS | $14.53 | twitter stocktwits trandingview |
Health Technology
| | O: -1.64% H: 0.0% C: 0.0%
NVO | $95.36 | twitter stocktwits trandingview |
Health Technology
| | O: -3.67% H: 0.0% C: 0.0%
LLY | News | $247.43 | twitter stocktwits trandingview |
Health Technology
| | O: -1.46% H: 0.0% C: 0.0%
ABT | News | $126.81 | twitter stocktwits trandingview |
Health Technology
| | O: -1.54% H: 0.0% C: 0.0%

growth hormone growth hormone
Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update
Published: 2022-01-07 (Crawled : 14:00) - biospace.com/
RVNC | $13.43 | twitter stocktwits trandingview |
Health Technology
| | O: 1.59% H: 0.0% C: 0.0%

financial results results
Global Local Anesthesia Drugs Market Outlook, 2026 - $3.37 Billion Opportunity Assessment by Drug Type, Mode of Administration, and Region
Published: 2021-12-31 (Crawled : 19:00) - prnewswire.com
BAX | $86.28 | twitter stocktwits trandingview |
Health Technology
| | O: -0.22% H: 0.53% C: -0.49%

drug
Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations
Published: 2021-12-30 (Crawled : 03:00) - prnewswire.com
VTRS | $14.53 | twitter stocktwits trandingview |
Health Technology
| | O: -0.37% H: 1.78% C: 0.3%
SNY | News 3 d | $52.125 | twitter stocktwits trandingview |
Health Technology
| | O: 0.08% H: 0.26% C: -0.2%

lantus als patent
Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results
Published: 2021-12-17 (Crawled : 23:00) - prnewswire.com
MYL | $15.86 | twitter stocktwits trandingview |
Health Technology

VTRS | $14.53 | twitter stocktwits trandingview |
Health Technology

results
Needle-Free Injections Market is Growing at a CAGR of 14.15% during the Forecast Period from 2021 to 2026 and will reach USD 24.12 billion by 2026, Affirms DelveInsight
Published: 2021-12-06 (Crawled : 17:00) - prnewswire.com
TRUMF | $37.612 | twitter stocktwits trandingview |
Health Technology
| | O: 0.5% H: 0.19% C: -2.25%
TRUMY | $37.18 | twitter stocktwits trandingview |
Manufacturing
| | O: 0.12% H: 0.2% C: 0.12%
NVO | $95.36 | twitter stocktwits trandingview |
Health Technology
| | O: 1.0% H: 0.0% C: 0.0%
WST | $367.8 | twitter stocktwits trandingview |
Health Technology
| | O: -1.59% H: 0.0% C: 0.0%
LLY | News | $247.43 | twitter stocktwits trandingview |
Health Technology
| | O: -2.2% H: 0.0% C: 0.0%
ABBV | News | $133.255 | twitter stocktwits trandingview |
Health Technology
| | O: 1.57% H: 0.0% C: 0.0%
JNJ | News | $165.98 | twitter stocktwits trandingview |
Health Technology
| | O: 1.49% H: 0.0% C: 0.0%

injection growing
Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent
Published: 2021-12-01 (Crawled : 16:00) - biospace.com/
VTRS | $14.53 | twitter stocktwits trandingview |
Health Technology
| | O: 0.89% H: 0.89% C: -2.66%

patent dating
Value-Based Pricing Paving Affordability & Enhancing Access to Generic Oncology Drugs to Reduce Cancer burden
Published: 2021-11-24 (Crawled : 12:30) - prnewswire.com
NVS | News | $87.83 | twitter stocktwits trandingview |
Health Technology
| | O: -0.41% H: 0.2% C: 0.11%
GSK | News | $45.1 | twitter stocktwits trandingview |
Health Technology
| | O: 0.85% H: 0.07% C: -0.17%
NVSEF | News | $88.6 | twitter stocktwits trandingview |
Health Technology
| | O: -0.76% H: 0.0% C: 0.0%
GLAXF | News | $21.82 | twitter stocktwits trandingview |
Health Technology
| | O: -1.8% H: 0.0% C: 0.0%

ford cancer drug
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying